Category Archives: Press Releases

Recruitment complete for Clarity’s PROPELLER prostate cancer diagnostic trial

Sydney, Australia 20 July 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the completion of recruitment for the Phase I PROPELLER diagnostic trial evaluating its 64Cu-SAR-bisPSMA product candidate in patients with untreated, confirmed prostate cancer, scheduled for radical prostatectomy.…

Leading Australian cancer expert joins Clarity’s Scientific Advisory Board

Sydney, Australia 29 June 2022 Highlights Professor Louise Emmett joins Clarity’s Scientific Advisory Board (SAB) She is deeply embedded in Australia’s multidisciplinary clinical development and cancer research efforts Professor Emmett will continue to be highly active and influential in progressing Clarity’s SAR Technology as both a collaborator and now as a SAB member Follows the…

IND approval from the US FDA for Phase II SAR-Bombesin imaging trial in prostate cancer

Sydney, Australia 6 June 2022 Highlights IND approval received for SAR-Bombesin product, enabling a Phase II “SABRE” imaging trial to detect prostate cancer in up to 50 PSMA-negative participants in the US Approximately 20% of prostate cancer patients with biochemical recurrence are PSMA-PET negative and therefore unsuitable for the currently approved PSMA targeting agents, presenting…

Clarity adds innovative nanobody IP to its Discovery pipeline

Sydney, Australia 31 May 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the acquisition of a targeted nanobody platform to its Discovery pipeline. The intellectual property, including a provisional patent and know-how, has been acquired from leading nanotechnology researcher…

Dr Neal Shore joins Clarity’s Clinical Advisory Board

Sydney, Australia 26 May 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that Dr Neal Shore has joined Clarity’s Clinical Advisory Board (CAB). Dr Shore MD, FACS is the Chief Medical Officer of Urology/Surgical Oncology at GenesisCare, US and…

Clarity confirms no supply issues to its ongoing clinical trials programs

Sydney, Australia 5 May 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, confirms Clarity and its clinical development programs are unaffected by Novartis’ recent suspension of production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at its facilities in Ivrea, Italy and Millburn, New Jersey. On…

First patient treated in the US-based prostate cancer imaging trial of Cu-64 SAR-bisPSMA

Sydney, Australia 21 April 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in the diagnostic US-based 64Cu SAR-bisPSMA trial for patients with biochemical recurrence (BCR) of prostate cancer. COBRA (Copper-64 SAR-bisPSMA in Biochemically Recurrent…

Dr Andrei Iagaru joins Clarity’s Scientific Advisory Board

Sydney, Australia 5 April 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that Dr Andrei Iagaru has joined Clarity’s Scientific Advisory Board (SAB). Dr Iagaru is a Professor of Radiology – Nuclear Medicine and the Chief of the Division of…

Appointment of Chief Financial Officer

Sydney, Australia 4 April 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the appointment of David Green as Chief Financial Officer (CFO). Outgoing CFO Robert Vickery will continue to serve as Company Secretary. Mr Green joins Clarity with over…

US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment

Sydney, Australia 28 March 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT052491271) for patients with prostate cancer is open for recruitment. COBRA (COpper-64 SAR-BisPSMA in Biochemically Recurrent prostAte cancer) is a Phase I/II Positron Emission…